A Comparison of Conventional and Hypofractionated Radiotherapy Schedules In the Treatment of Localized Prostate Cancer

Mok, Gary; Martin, Jarad; Massey, Christine; Bayley, A.; Ménard, Cynthia; Chung, Peter; Bristow, R.G.; Warde, Padraig; Gospodarowicz, Mary K.; Catton, C.

doi:10.1016/j.ijrobp.2011.06.648

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 606 records, of which 13 reports of 12 comparative trials (6 randomized-controlled trials [3,10,11,[19][20][21][22][23], 3 cohort studies [22,[24][25][26], and 3 retrospective case-control studies [22,27,28]) with a total of 4,572 participants (see Fig. S1).…”

Section: Literature Research and Characteristics Of Studiesmentioning

confidence: 99%

Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis

et al. 2014

View full text Add to dashboard Cite

The aim of this study is to explore the oncological outcomes of hypofractionated radiotherapy for patients with prostate cancer. We systematically searched PubMed, Embase, and the Cochrane Library prior to April 2014 and references of relevant original papers and review articles. Unpublished data from meeting abstracts were supplemented. Studies comparing hypofractionated with conventionally fractionated radiotherapy (CFRT) on oncological outcomes of patients with clinically localized prostate cancer were included. Twelve distinct datasets involving 4,572 participants from 13 papers were eligible for this meta-analysis. The biochemical failure rate (BFR) decreases significantly in the hypofractionated radiotherapy (HFRT) group for approximately 30 % (11-43 %). However, no significantly lower prostate cancer-specific survival and overall survival in HFRT group were observed. In subgroup analyses, HFRT without radiation doses reduction was especially effective in controlling BFR (HR = 0.71, 95 % CI 0.53-0.95; P = 0.02). Compared to CFRT, HFRT only yield a consistent advantage on BFR in high-risk patients (HR = 0.61, 95 % CI 0.46-0.82; P = 0.001). Moreover, androgen deprivation therapy (ADT) had no effect on two radiotherapies in controlling BFR. HFRT improves biochemical failure-free survival in patients with clinically localized prostate cancer. Further well-designed trial is needed to confirm our findings.

show abstract

Section: Literature Research and Characteristics Of Studiesmentioning

confidence: 99%

Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Other studies have determined a general biochemical control rate of 83% at 5 years. Our patients, with one year follow up, are low PSA levels, none has achieved an increase that meets the established class definition for biochemical failure in Phoenix; to date our control is 100%, considering it is a study program at a single institution hypofractionation reporting preliminary results [13][14][15][16][17][18][19].…”

Section: Discussionmentioning

confidence: 83%

Untitled

2015

JCPCR

View full text Add to dashboard Cite

Objective: Get free interval biochemical failure and toxicity in patients treated with hypofractionated radiotherapy (HFRT, for its acronym in English, Hypofractionated Radiation Therapy) with IMRT (Intensity Modulated Radiation Therapy), administering 70 Gy in 28 fractions of 2.5 Gy. Methods:In May 2013 began in CDD Radioterapia Radioterapia Unit of Radiotherapy and Radiosurgery of Clinica Abreu, an hypofractionation program with IMRT as an alternative treatment for patients with localized prostate cancer favorable risk. The four selected patients had histologically confirmed prostate adenocarcinoma without prior radical treatment and categorized as low risk according to the criteria of D'Amico et al. For each patient a treatment plan is made based on Intensity Modulated Radiation Therapy (IMRT) more Image Guided Radiation Therapy (IGRT) with 18 MV photons from a linear accelerator CLINAC 21iX of the prestigious brand Varian®, administering doses of 70 Gy in 28 fractions of 2.5 Gy/day using an α/β 3, biologically equivalent to 76 Gy in 38 fractions of 2 Gy, under-Quadratic Linear Model. Patients were followed every 3 months for 18 months. The gastrointestinal and genitourinary toxicity (GI) (GU), was evaluated prospectively and classified according to the criteria of the RTOG (Radiation Therapy Oncology Group). As a definition of biochemical failure we use the RTOG criteria (definition Phoenix), considered the elevation of postradiotherapy PSA≥2 ng/mL above the nadir.Results: During follow-up of 18 months, all patients (100%) were free of biochemical failure. Only one patient presented grade 2 acute genitourinary toxicity, without having reported genitourinary or gastrointestinal late toxicity. This study is preliminary, with short follow and discreet patient population, however, is the first program and the first publication of hypofractionated treatment for prostate cancer radiotherapy in our country. Conclusion:Hypofractionated Radiotherapy (HFRT) is a valuable treatment option for patients with favorable risk prostate cancer, with an excellent result of biochemical control and low toxicity.

show abstract

Hypofractionated Radiotherapy in Low Risk Prostate Cancer: Preliminary Experience

Sánchez¹

2015

JCPCR

View full text Add to dashboard Cite

Objective: Get free interval biochemical failure and toxicity in patients treated with hypofractionated radiotherapy (HFRT, for its acronym in English, Hypofractionated Radiation Therapy) with IMRT (Intensity Modulated Radiation Therapy), administering 70 Gy in 28 fractions of 2.5 Gy. Methods:In May 2013 began in CDD Radioterapia Radioterapia Unit of Radiotherapy and Radiosurgery of Clinica Abreu, an hypofractionation program with IMRT as an alternative treatment for patients with localized prostate cancer favorable risk. The four selected patients had histologically confirmed prostate adenocarcinoma without prior radical treatment and categorized as low risk according to the criteria of D'Amico et al. For each patient a treatment plan is made based on Intensity Modulated Radiation Therapy (IMRT) more Image Guided Radiation Therapy (IGRT) with 18 MV photons from a linear accelerator CLINAC 21iX of the prestigious brand Varian®, administering doses of 70 Gy in 28 fractions of 2.5 Gy/day using an α/β 3, biologically equivalent to 76 Gy in 38 fractions of 2 Gy, under-Quadratic Linear Model. Patients were followed every 3 months for 18 months. The gastrointestinal and genitourinary toxicity (GI) (GU), was evaluated prospectively and classified according to the criteria of the RTOG (Radiation Therapy Oncology Group). As a definition of biochemical failure we use the RTOG criteria (definition Phoenix), considered the elevation of postradiotherapy PSA≥2 ng/mL above the nadir. Results:During follow-up of 18 months, all patients (100%) were free of biochemical failure. Only one patient presented grade 2 acute genitourinary toxicity, without having reported genitourinary or gastrointestinal late toxicity. This study is preliminary, with short follow and discreet patient population, however, is the first program and the first publication of hypofractionated treatment for prostate cancer radiotherapy in our country. Conclusion:Hypofractionated Radiotherapy (HFRT) is a valuable treatment option for patients with favorable risk prostate cancer, with an excellent result of biochemical control and low toxicity.

show abstract

A Comparison of Conventional and Hypofractionated Radiotherapy Schedules In the Treatment of Localized Prostate Cancer

Cited by 3 publications

References 0 publications

Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis

Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis

Untitled

Hypofractionated Radiotherapy in Low Risk Prostate Cancer: Preliminary Experience

Contact Info

Product

Resources

About